小儿豉翘清热颗粒中 2 种成分在正常及炎症模型大鼠体内的药动学比较研究

    Comparative Study on Pharmacokinetics of Two Components from Xiao’er Chiqiao Qingre Granules in Normal and Inflammatory Rats

    • 摘要:
      目的 考察小儿豉翘清热颗粒中栀子苷、芍药苷在正常及炎症模型大鼠体内药动学行为差异。
      方法 20只大鼠随机分为 正常组和模型组,模型组隔天腹腔注射给予 0.5 mg·kg−1脂多糖(LPS),持续 2 周,构建 SD大鼠炎症模型,第7次腹腔注射时给予 1 mg·kg−1 LPS。造模同时,正常组给予等剂量生理盐水。造模成功后,正常组及炎症模型组大鼠分别灌胃小儿豉翘清热颗粒混悬液3.75 g·kg−1,采集血浆样品,经蛋白沉淀-液液萃取方法处理后,采用LC-MS/MS测定栀子苷、芍药苷浓度,Phoenix Winnolin 6.3软件计算药动学参数。
      结果 小儿豉翘清热颗粒灌胃给药后,正常组及模型组大鼠体内栀子苷的 AUC0-t分别为(293.36±59.96)和(379.57±194.96)μg·L−1·h,Cmax 分别为 (78.15±25.88)和(82.63±40.45)μg·L−1Tmax分别为(0.60±0.32)和(0.73±0.38)h,t1/2 分别为(1.72±0.70)和(1.56±0.53)h,CLZ/F分别为 (68.10±13.03)和(66.94±36.20)L·h−1·kg−1VZ/F分别为(168.41±77.55)和(153.51±106.9)L·kg−1;芍药苷的 AUC0-t 分别为(162.82±24.41) 和(138.34±39.54)μg·L−1·h,Cmax 分别为 (35.85±4.31)和(30.39±8.94)μg·L−1Tmax 分别为 (0.70±0.47)和(0.78±0.72)h,t1/2 分别为(4.61±3.80)和(4.10±1.87)h,CLZ/F分别为(72.52±19.40)和(87.57±21.88)L·h−1·kg−1VZ/F分别为(404.18±163.58)和(503.29±260.04)L·kg−1。各参数在正常组与模型组之间均无显著性差异。
      结论 炎症状态对小儿豉翘清热颗粒给药后大鼠体内栀子苷、芍药苷的药动学行为无显著影响。

       

      Abstract:
      OBJECTIVE To investigate pharmacokinetic differences of geniposide and paeoniflorin in normal and inflammatory rats after Xiao’er Chiqiao Qingre granules(XECQ) administration.
      METHODS Twenty rats were randomly divided into two groups, rats in the model group were intraperitoneal injected with 0.5 mg·kg−1 LPS every other day for six times and 1 mg·kg−1 LPS at the last time. Rats in the control group received equal dose of physiological saline at all the same time. After two weeks model making, all rats were oral administration with 3.75 g·kg−1 XECQ. Rat plasma samples were then collected at different time points and treated with protein precipitation-liquid-liquid extraction methods for LC-MS/MS analysis to obtain concentration data. The pharmacokinetic parameters were calculated by Phoenix Winnolin 6.3.
      RESULTS After XECQ administration, the main pharmacokinetic parameters of geniposide in control and model group were obtained as follows: AUC0-t was (293.36±59.96) and (379.57±194.96)μg·L−1·h, Cmax was (78.15±25.88) and (82.63±40.45)μg·L−1, Tmax was (0.60±0.32) and (0.73±0.38)h, t1/2 was (1.72±0.70) and (1.56±0.53)h, CLZ/F was (68.10±13.03) and (66.94±36.20)L·h−1·kg−1, VZ/F was (168.41±77.55) and (153.51±106.9)L·kg−1. The main pharmacokinetic parameters of paeoniflorin in control and model group were obtained as follows: AUC0-t was (162.82±24.41) and (138.34±39.54)μg·L−1·h, Cmax was (35.85±4.31) and (30.39±8.94)μg·L−1, Tmax was (0.70±0.47) and (0.78±0.72)h, t1/2 was (4.61±3.80) and (4.10±1.87)h, CLZ/F was (72.52±19.40) and (87.57±21.88)L·h−1·kg−1, VZ/F was (404.18±163.58) and (503.29±260.04)L·kg−1. Compared with the control group, no significant differences in pharmacokinetic parameters of geniposide and paeoniflorin were observed in the model group.
      CONCLUSION Inflammatory condition may have few effect on pharmacokinetic behaviors of geniposide and paeoniflorin in rats after XECQ administration.

       

    /

    返回文章
    返回